Get the Stockscreener App
8.17
0.25%
0.02
Terns Pharmaceuticals Inc stock is traded at $8.17, with a volume of 50,587.
It is up +0.25% in the last 24 hours and up +13.00% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$8.15
Open:
$8.16
24h Volume:
50,587
Relative Volume:
0.05
Market Cap:
$715.84M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-6.1894
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
-3.08%
1M Performance:
+13.00%
6M Performance:
+281.78%
1Y Performance:
+6.52%
1-Day Range:
$8.073
$8.22
1-Week Range:
$7.976
$8.6214
52-Week Range:
$1.865
$8.7799
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
8.18 | 713.22M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.75 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.47 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.40 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.18 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Tick level data insight on Terns Pharmaceuticals Inc. volatility2025 Short Interest & Capital Efficiency Focused Ideas - newser.com
Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN
What analysts say about Terns Pharmaceuticals Inc stockMean Reversion Trades & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Detecting price anomalies in Terns Pharmaceuticals Inc. with AIPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Using data models to predict Terns Pharmaceuticals Inc. stock movementQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Is it too late to sell Terns Pharmaceuticals Inc.2025 Year in Review & High Accuracy Trade Alerts - newser.com
Terns Pharmaceuticals Inc Stock Analysis and ForecastCup and Handle Formations & Interactive Charts for Smarter Trading - earlytimes.in
How Terns Pharmaceuticals Inc. stock valuations compare to rivalsMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
How to recover losses in Terns Pharmaceuticals Inc. stockWeekly Stock Recap & Growth Focused Entry Reports - newser.com
Terns Pharmaceuticals (NASDAQ:TERN) Receives Sell (D-) Rating from Weiss Ratings - Defense World
Predicting Terns Pharmaceuticals Inc. trend using moving averages2025 Key Lessons & Fast Gain Stock Tips - newser.com
Volume spikes in Terns Pharmaceuticals Inc. stock – what they meanJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule ... - Enidnews.com
118,000-share grant: Terns Pharmaceuticals awards inducement options at $7.81 with 10-year term - Stock Titan
MarketsMedicine Hat News - FinancialContent
Does Terns Pharmaceuticals Inc. qualify in momentum factor screeningPortfolio Gains Report & Long Hold Capital Preservation Plans - newser.com
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely - Yahoo Finance
Terns Pharmaceuticals: Valued As If It Can't Win - Seeking Alpha
Is Terns Pharmaceuticals Inc a good long term investmentRisk Adjusted Returns & High Yield Stock Picks - earlytimes.in
Will Terns Pharmaceuticals Inc. stock see insider buyingDollar Strength & Daily Entry Point Alerts - The British Mountaineering Council
Exchange Traded Concepts LLC Grows Stock Position in Terns Pharmaceuticals, Inc. $TERN - Defense World
Full technical analysis of Terns Pharmaceuticals Inc. stockTrade Entry Summary & Long-Term Safe Investment Ideas - newser.com
Goldman Sachs Group Inc. Has $1.15 Million Stock Position in Terns Pharmaceuticals, Inc. $TERN - Defense World
Technical analysis overview for Terns Pharmaceuticals Inc. stockWeekly Trade Summary & Verified Short-Term Trading Plans - newser.com
Can Terns Pharmaceuticals Inc. rally from current levels2025 Momentum Check & Daily Stock Momentum Reports - newser.com
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
2 Under-the-Radar Stocks That Could Soar - Mitrade
Fed Meeting: Is Terns Pharmaceuticals Inc a top pick in the sectorJuly 2025 Opening Moves & Fast Gain Swing Alerts - خودرو بانک
Aug Wrap: Is Terns Pharmaceuticals Inc stock a good dividend stockWeekly Stock Analysis & Fast Exit Strategy with Risk Control - خودرو بانک
Analyzing Terns Pharmaceuticals Inc. with multi timeframe charts2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
How high can Terns Pharmaceuticals Inc. stock goQuarterly Portfolio Report & Consistent Return Strategy Ideas - newser.com
Published on: 2025-09-19 23:29:17 - خودرو بانک
Profit Review: Will Terns Pharmaceuticals Inc benefit from current market trendsJuly 2025 Fed Impact & Precise Entry and Exit Recommendations - خودرو بانک
Trend analysis for Terns Pharmaceuticals Inc. this weekBreakout Watch & Real-Time Volume Analysis Alerts - newser.com
Identifying reversal signals in Terns Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Statistical indicators supporting Terns Pharmaceuticals Inc.’s strength2025 Price Targets & Smart Swing Trading Techniques - newser.com
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Buy Signal: How cyclical is First Bancorp’s revenue streamTake Profit & AI Enhanced Execution Alerts - khodrobank.com
Short Covering: Is Aviat Networks Inc. subject to activist investor interestMarket Growth Review & Stock Timing and Entry Methods - khodrobank.com
Terns Pharmaceuticals (NASDAQ:TERN) Research Coverage Started at Barclays - Defense World
What’s the recovery path for long term holders of Terns Pharmaceuticals Inc.2025 Top Gainers & High Conviction Buy Zone Alerts - newser.com
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Terns Pharmaceuticals Inc Stock (TERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kuriakose Emil | Chief Medical Officer |
Jul 01 '25 |
Sale |
4.27 |
853 |
3,640 |
52,464 |
| Gengos Andrew | Chief Financial Officer |
Jun 27 '25 |
Buy |
3.93 |
10,000 |
39,283 |
25,000 |
| Burroughs Amy L. | Chief Executive Officer |
Jun 25 '25 |
Buy |
3.87 |
23,314 |
90,230 |
47,083 |
| Gengos Andrew | Chief Financial Officer |
Jun 13 '25 |
Buy |
3.73 |
10,000 |
37,350 |
10,000 |
| Gengos Andrew | Chief Financial Officer |
Jun 16 '25 |
Buy |
3.95 |
5,000 |
19,732 |
15,000 |
| Kuriakose Emil | Chief Medical Officer |
Apr 01 '25 |
Sale |
2.49 |
952 |
2,366 |
53,317 |
| Jung Melita Sun | Chief Business Officer |
Nov 30 '24 |
Buy |
5.11 |
2,250 |
11,498 |
2,250 |
| Burroughs Amy L. | Chief Executive Officer |
Nov 30 '24 |
Buy |
5.11 |
510 |
2,606 |
19,609 |
| Kuriakose Emil | Chief Medical Officer |
Jan 02 '25 |
Sale |
5.71 |
4,481 |
25,607 |
54,269 |
| Vignola Mark J. | Chief Financial Officer |
Jan 06 '25 |
Sale |
5.80 |
9,059 |
52,500 |
74,752 |
0.21%
2.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):